Skip to Content
Interactive Textbook on Clinical Symptom Research Logo


Home Button

Oral Mucositis
Author Bios
Introduction
Etiology of Oral Mucositis
Prevalence
Currently selected section: Diagnosis
Treatment
Biological Mechanisms of Mucositis
Assessment Scale
Clinical Trial Design
Population Selection and Randomization
Data Collection and Assessment Measures
Quality Control Techniques
Anaysis and Presentation
Conclusion


Chapter 17: Oral Mucositis: Diagnosis of Oral Mucositis
        

Ulcerative mucositis typically appears in the non-keratinized surfaces of the oral cavity, for instance the inner surfaces of the cheeks and lips, the floor of the mouth, the lateral and bottom surfaces of the tongue, and the soft palate. Some studies have also reported a distribution of these lesions on keratinized surfaces such as the hard palate and upper surface of the tongue. If ulcerations are noted in these areas, cultures and/or biopsies should be taken from the lesions to rule out viral infections or other causes. Redness and/or ulcerations, ranging from a few millimeters to a few centimeters long, can appear. Bleeding from the ulcerations is common; however, bleeding often reflects a severe reduction in a patient's platelet count, a condition called thrombocytopenia.

Due to the concurrent loss of white blood cells with thrombocytopenia, bleeding can result from the mouth, throat and/or along the gastrointestinal tract. In the past uncontrolled bleeding from the mouth from oral mucositis was common, but such bleeding is rarely seen today due to the availability of platelet infusions and better therapeutic regimens. If blood is seen in the mouth, assessing the source is important and often difficult.

Other associated chemotherapeutic complications can appear as ulcerative mucositis, namely acute graft-versus-host disease (GVHD) in bone marrow transplantation patients and herpes simplex virus (HSV) infections. Determining the cause of oral ulcers can be challenging. Culturing or taking a biopsy of an unusual ulcer is recommended to rule out infections.

The prevalence of acute GVHD ranges from 18% to 70% of bone marrow patients who receive marrow grafts from other persons (as opposed to themselves) (Sullivan et al., 1983; Hood et al., 1987). Acute GVHD can present as ulcers, large fluid-filled blisters (bullae), or desquamation. (Woo et al., 1993;Woo et al., 1997). However, GVHD ulcerative lesions often appear when the patient's absolute neutrophil count has recovered enough to indicate the successful integration of the marrow graft. In addition, other signs and symptoms of acute GVHD typically appear concurrently in multiple areas of the body, such as the gastrointestinal tract and skin, suggesting that the oral lesions are GVHD-related. Herpes lesions can also present as oral ulcers. Prior to the prophylactic use of the antiviral agent acylcovir for all bone marrow transplant recipients, herpes was confirmed in 68%-90% of oral lesions (Wade et al., 1984; Saral et al., 1981; Gluckman et al., 1983). Currently, herpes-related mucositis is rarely seen in patients undergoing bone marrow transplantation. However, herpetic lesions are often seen in patients undergoing chemotherapy or radiation treatment.

Diagnosis of herpes versus mucositis ulcerative oral lesions can be complicated. Herpetic lesions tend to be seen in both keratinized and non-keratinized areas intraorally (Woo et al., 1990). Ulcerative mucositis is predominantly seen in the non-keratinized tissues as mentioned above. Suspected herpetic lesions should be cultured because these lesions predispose patients to secondary infections, which can potentially cause breakthrough dissemination of the virus causing organ involvement.

Oral manifestations that can be seen in bone marrow recipients and patients undergoing chemotherapy or radiotherapy are:


Page 5 of 21
Previous Section